Misplaced Pages

Coblopasvir

Legal status
Legal status	In general: ℞ (Prescription only)
Identifiers
IUPAC name Methyl N-pyrrolidin-2-yl]-1H-imidazol-5-yl]-1,3-benzodioxol-4-yl]phenyl]-1H-imidazol-2-yl]pyrrolidin-1-yl]-3-methyl-1-oxobutan-2-yl]carbamate
CAS Number	1312608-46-0
PubChem CID	58316387
DrugBank	DB15315
ChemSpider	75531292
UNII	67XWL3R65W
KEGG	D12247
Chemical and physical data
Formula	C41H50N8O8
Molar mass	782.899 g·mol
InChI InChI=InChI=1S/C41H50N8O8/c1-22(2)32(46-40(52)54-5)38(50)48-17-7-9-30(48)36-42-19-28(44-36)25-13-11-24(12-14-25)26-15-16-27(35-34(26)56-21-57-35)29-20-43-37(45-29)31-10-8-18-49(31)39(51)33(23(3)4)47-41(53)55-6/h11-16,19-20,22-23,30-33H,7-10,17-18,21H2,1-6H3,(H,42,44)(H,43,45)(H,46,52)(H,47,53)/t30-,31-,32-,33-/m0/s1 Key:JBYJTCVXUMWTJJ-YRCZKMHPSA-N

Coblopasvir is a pharmaceutical drug for the treatment of hepatitis C. It is a pan-genotypic inhibitor of HCV nonstructural protein 5A.

In China, it is approved for use in combination with sofosbuvir for treating naïve or interferon‐experienced adults chronically monoinfected patients with HCV of genotype 1, 2, 3 and 6, with or without compensated cirrhosis.

References

1. Rao H, Song G, Li G, Yang Y, Wu X, Guan Y, et al. (January 2020). "Safety and efficacy of coblopasvir and sofosbuvir in patients with genotypes 1, 2, 3 and 6 HCV infections without or with compensated cirrhosis". Journal of Viral Hepatitis. 27 (1): 45–51. doi:10.1111/jvh.13208. PMID 31520460.
2. ^ Gao Y, Kong F, Li G, Li C, Zheng S, Lin J, et al. (November 2020). "Coblopasvir and sofosbuvir for treatment of chronic hepatitis C virus infection in China: A single-arm, open-label, phase 3 trial". Liver International. 40 (11): 2685–2693. doi:10.1111/liv.14633. PMC 7702130. PMID 33047868.

This antiinfective drug article is a stub. You can help Misplaced Pages by expanding it.

• v
• t
• e

• NS5A inhibitors
• Benzodioxoles
• Imidazoles
• Methyl esters
• Carbamates
• Isopropyl compounds
• Pyrrolidines
• Antiinfective agent stubs